Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.

Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.

Publication date: Jan 01, 2025

A total of 5011 adult volunteers attending vaccination centers in different regions of Colombia were enrolled in a 1-year prospective observational cohort study to evaluate the immunogenicity and effectiveness of SARS-CoV-2-based vaccines as part of a National Vaccine Program established to contain the COVID-19 pandemic. Following informed consent, 5,011 participants underwent a sociodemographic survey and PCR testing to assess SARS-CoV-2 infection. Blood samples were collected, and serum fractions were obtained from a participant subsample (n = 3441) at six-time points to assess virus-specific IgG responses to the Spike protein, its Receptor Binding Domain, and the Nucleoprotein by ELISA. Additionally, antibody-neutralizing activity was evaluated using a cPass SARS-CoV-2 neutralization kit. Most participants (95. 8%; n = 4802) received between one Ad26. COV2. S (Janssen vaccine) and four vaccine doses of BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac), with some receiving vaccine combinations; a small group, 4. 2% (n = 209), remained unvaccinated. Throughout the study, only 8. 76% (n = 439) of the participants tested positive for SARS-CoV-2 by PCR. Notably, all participants seroconverted for IgG antibodies, with high seropositivity rates for S (99. 8%; n = 4795), RBD (99. 7%; n = 1691), and N (92. 7%; n = 3072) proteins. Moreover, significant (92%-97%) neutralizing activity was observed for all four SARS-CoV-2 circulating variants. This study highlights the importance of assessing the duration of the IgG response to SARS-CoV-2 elicited by vaccination and infection, and the antibody neutralizing activity as a potential surrogate marker of protection. These findings provide important insight for further strengthening the vaccination strategies to control COVID-19.

Concepts Keywords
Bnt162b2 2019-nCoV Vaccine mRNA-1273
Colombia 2019-nCoV Vaccine mRNA-1273
Pandemic Adolescent
Pcr Adult
Vaccination Aged
Antibodies, Neutralizing
Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
antibody
Antibody Formation
BNT162 Vaccine
BNT162 Vaccine
Colombia
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
COVID‐19
Female
Follow-Up Studies
Humans
Immunogenicity, Vaccine
Immunoglobulin G
Immunoglobulin G
Longitudinal Studies
Male
Middle Aged
neutralization
Prospective Studies
SARS-CoV-2
SARS‐CoV‐2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination
vaccines
Young Adult

Semantics

Type Source Name
disease MESH COVID-19 pandemic
pathway REACTOME SARS-CoV-2 Infection
disease IDO blood
disease IDO protein
disease MESH infection

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *